nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—SCN5A—dilated cardiomyopathy	0.321	0.481	CbGaD
Lidocaine—SLC22A5—dilated cardiomyopathy	0.185	0.277	CbGaD
Lidocaine—EGFR—dilated cardiomyopathy	0.161	0.241	CbGaD
Lidocaine—SLC22A5—Furosemide—dilated cardiomyopathy	0.0781	0.427	CbGbCtD
Lidocaine—CYP2C8—Spironolactone—dilated cardiomyopathy	0.0428	0.234	CbGbCtD
Lidocaine—ABCB1—Lisinopril—dilated cardiomyopathy	0.0329	0.18	CbGbCtD
Lidocaine—ABCB1—Spironolactone—dilated cardiomyopathy	0.029	0.159	CbGbCtD
Lidocaine—SCN5A—purkinje fiber—dilated cardiomyopathy	0.025	0.38	CbGeAlD
Lidocaine—SCN5A—endocardium—dilated cardiomyopathy	0.0129	0.196	CbGeAlD
Lidocaine—SCN5A—sinoatrial node—dilated cardiomyopathy	0.0122	0.186	CbGeAlD
Lidocaine—CYP2C9—cardial valve—dilated cardiomyopathy	0.00643	0.0979	CbGeAlD
Lidocaine—Etidocaine—SCN5A—dilated cardiomyopathy	0.00285	0.464	CrCbGaD
Lidocaine—EGFR—heart—dilated cardiomyopathy	0.00125	0.019	CbGeAlD
Lidocaine—Local reaction—Furosemide—dilated cardiomyopathy	0.00121	0.0408	CcSEcCtD
Lidocaine—SCN5A—cardiac ventricle—dilated cardiomyopathy	0.00108	0.0165	CbGeAlD
Lidocaine—SCN5A—myocardium—dilated cardiomyopathy	0.00102	0.0155	CbGeAlD
Lidocaine—Mepivacaine—SCN5A—dilated cardiomyopathy	0.00101	0.165	CrCbGaD
Lidocaine—Blister—Furosemide—dilated cardiomyopathy	0.000927	0.0314	CcSEcCtD
Lidocaine—SCN4A—heart—dilated cardiomyopathy	0.000917	0.014	CbGeAlD
Lidocaine—Ropivacaine—SCN5A—dilated cardiomyopathy	0.000798	0.13	CrCbGaD
Lidocaine—Tocainide—SCN5A—dilated cardiomyopathy	0.000751	0.122	CrCbGaD
Lidocaine—SCN3A—heart—dilated cardiomyopathy	0.000713	0.0109	CbGeAlD
Lidocaine—SCN5A—heart—dilated cardiomyopathy	0.000711	0.0108	CbGeAlD
Lidocaine—Throat sore—Lisinopril—dilated cardiomyopathy	0.000695	0.0235	CcSEcCtD
Lidocaine—Oropharyngeal discomfort—Lisinopril—dilated cardiomyopathy	0.000689	0.0233	CcSEcCtD
Lidocaine—Drowsiness—Spironolactone—dilated cardiomyopathy	0.000687	0.0232	CcSEcCtD
Lidocaine—Ventricular fibrillation—Lisinopril—dilated cardiomyopathy	0.000655	0.0221	CcSEcCtD
Lidocaine—SLC22A5—cardiac ventricle—dilated cardiomyopathy	0.000629	0.00958	CbGeAlD
Lidocaine—SCN5A—cardiac atrium—dilated cardiomyopathy	0.000608	0.00926	CbGeAlD
Lidocaine—Lightheadedness—Furosemide—dilated cardiomyopathy	0.000598	0.0202	CcSEcCtD
Lidocaine—SLC22A5—myocardium—dilated cardiomyopathy	0.000592	0.00901	CbGeAlD
Lidocaine—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.000551	0.0187	CcSEcCtD
Lidocaine—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.000507	0.0172	CcSEcCtD
Lidocaine—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.000501	0.017	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.000501	0.017	CcSEcCtD
Lidocaine—Neuropathy—Lisinopril—dilated cardiomyopathy	0.000471	0.0159	CcSEcCtD
Lidocaine—Procainamide—SCN5A—dilated cardiomyopathy	0.000464	0.0756	CrCbGaD
Lidocaine—Urinary retention—Furosemide—dilated cardiomyopathy	0.000461	0.0156	CcSEcCtD
Lidocaine—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.000448	0.0152	CcSEcCtD
Lidocaine—Confusional state—Spironolactone—dilated cardiomyopathy	0.000442	0.0149	CcSEcCtD
Lidocaine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.000438	0.0148	CcSEcCtD
Lidocaine—SLC22A5—heart—dilated cardiomyopathy	0.000413	0.00629	CbGeAlD
Lidocaine—Somnolence—Spironolactone—dilated cardiomyopathy	0.000389	0.0132	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000378	0.0128	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.000376	0.0127	CcSEcCtD
Lidocaine—Drowsiness—Furosemide—dilated cardiomyopathy	0.000374	0.0126	CcSEcCtD
Lidocaine—Diplopia—Lisinopril—dilated cardiomyopathy	0.000364	0.0123	CcSEcCtD
Lidocaine—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.000364	0.0123	CcSEcCtD
Lidocaine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.000361	0.0122	CcSEcCtD
Lidocaine—CYP2B6—heart—dilated cardiomyopathy	0.000359	0.00546	CbGeAlD
Lidocaine—CYP2C9—heart—dilated cardiomyopathy	0.000355	0.00541	CbGeAlD
Lidocaine—SLC22A5—cardiac atrium—dilated cardiomyopathy	0.000353	0.00538	CbGeAlD
Lidocaine—Urticaria—Spironolactone—dilated cardiomyopathy	0.000348	0.0118	CcSEcCtD
Lidocaine—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.000346	0.0117	CcSEcCtD
Lidocaine—Visual impairment—Furosemide—dilated cardiomyopathy	0.000323	0.0109	CcSEcCtD
Lidocaine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000323	0.0109	CcSEcCtD
Lidocaine—Asthma—Lisinopril—dilated cardiomyopathy	0.000314	0.0106	CcSEcCtD
Lidocaine—Eye disorder—Furosemide—dilated cardiomyopathy	0.000314	0.0106	CcSEcCtD
Lidocaine—Tinnitus—Furosemide—dilated cardiomyopathy	0.000313	0.0106	CcSEcCtD
Lidocaine—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.000309	0.0105	CcSEcCtD
Lidocaine—Sweating increased—Lisinopril—dilated cardiomyopathy	0.000306	0.0104	CcSEcCtD
Lidocaine—Angiopathy—Furosemide—dilated cardiomyopathy	0.000304	0.0103	CcSEcCtD
Lidocaine—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000303	0.0103	CcSEcCtD
Lidocaine—Erythema—Furosemide—dilated cardiomyopathy	0.000292	0.00988	CcSEcCtD
Lidocaine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00029	0.0098	CcSEcCtD
Lidocaine—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000286	0.00968	CcSEcCtD
Lidocaine—Vomiting—Spironolactone—dilated cardiomyopathy	0.000279	0.00942	CcSEcCtD
Lidocaine—Rash—Spironolactone—dilated cardiomyopathy	0.000276	0.00935	CcSEcCtD
Lidocaine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000276	0.00934	CcSEcCtD
Lidocaine—Vision blurred—Furosemide—dilated cardiomyopathy	0.000275	0.00931	CcSEcCtD
Lidocaine—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.000275	0.0093	CcSEcCtD
Lidocaine—Headache—Spironolactone—dilated cardiomyopathy	0.000274	0.00929	CcSEcCtD
Lidocaine—Agitation—Furosemide—dilated cardiomyopathy	0.000268	0.00908	CcSEcCtD
Lidocaine—Procainamide—SLC22A5—dilated cardiomyopathy	0.000267	0.0435	CrCbGaD
Lidocaine—Nausea—Spironolactone—dilated cardiomyopathy	0.00026	0.0088	CcSEcCtD
Lidocaine—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000256	0.00867	CcSEcCtD
Lidocaine—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000252	0.00854	CcSEcCtD
Lidocaine—Confusional state—Furosemide—dilated cardiomyopathy	0.00024	0.00813	CcSEcCtD
Lidocaine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000238	0.00806	CcSEcCtD
Lidocaine—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000235	0.00794	CcSEcCtD
Lidocaine—Shock—Furosemide—dilated cardiomyopathy	0.000235	0.00793	CcSEcCtD
Lidocaine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000234	0.00791	CcSEcCtD
Lidocaine—Flushing—Lisinopril—dilated cardiomyopathy	0.000234	0.0079	CcSEcCtD
Lidocaine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00023	0.0078	CcSEcCtD
Lidocaine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000228	0.00773	CcSEcCtD
Lidocaine—Chills—Lisinopril—dilated cardiomyopathy	0.000226	0.00764	CcSEcCtD
Lidocaine—Hypotension—Furosemide—dilated cardiomyopathy	0.000223	0.00754	CcSEcCtD
Lidocaine—Erythema—Lisinopril—dilated cardiomyopathy	0.000219	0.00741	CcSEcCtD
Lidocaine—Tension—Lisinopril—dilated cardiomyopathy	0.000215	0.00728	CcSEcCtD
Lidocaine—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000215	0.00726	CcSEcCtD
Lidocaine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000214	0.00724	CcSEcCtD
Lidocaine—Nervousness—Lisinopril—dilated cardiomyopathy	0.000213	0.0072	CcSEcCtD
Lidocaine—Back pain—Lisinopril—dilated cardiomyopathy	0.000212	0.00717	CcSEcCtD
Lidocaine—Somnolence—Furosemide—dilated cardiomyopathy	0.000212	0.00717	CcSEcCtD
Lidocaine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000207	0.00699	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000206	0.00696	CcSEcCtD
Lidocaine—Tremor—Lisinopril—dilated cardiomyopathy	0.000205	0.00695	CcSEcCtD
Lidocaine—Pain—Furosemide—dilated cardiomyopathy	0.000204	0.0069	CcSEcCtD
Lidocaine—Angioedema—Lisinopril—dilated cardiomyopathy	0.0002	0.00677	CcSEcCtD
Lidocaine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000196	0.00665	CcSEcCtD
Lidocaine—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000193	0.00652	CcSEcCtD
Lidocaine—ABCB1—heart—dilated cardiomyopathy	0.000192	0.00292	CbGeAlD
Lidocaine—Urticaria—Furosemide—dilated cardiomyopathy	0.000189	0.00641	CcSEcCtD
Lidocaine—Chest pain—Lisinopril—dilated cardiomyopathy	0.000187	0.00631	CcSEcCtD
Lidocaine—Anxiety—Lisinopril—dilated cardiomyopathy	0.000186	0.00629	CcSEcCtD
Lidocaine—Confusional state—Lisinopril—dilated cardiomyopathy	0.00018	0.0061	CcSEcCtD
Lidocaine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000179	0.00605	CcSEcCtD
Lidocaine—Oedema—Lisinopril—dilated cardiomyopathy	0.000179	0.00605	CcSEcCtD
Lidocaine—Shock—Lisinopril—dilated cardiomyopathy	0.000176	0.00595	CcSEcCtD
Lidocaine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000176	0.00594	CcSEcCtD
Lidocaine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000173	0.00585	CcSEcCtD
Lidocaine—Asthenia—Furosemide—dilated cardiomyopathy	0.000171	0.00579	CcSEcCtD
Lidocaine—Hypotension—Lisinopril—dilated cardiomyopathy	0.000167	0.00565	CcSEcCtD
Lidocaine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000161	0.00543	CcSEcCtD
Lidocaine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000159	0.00539	CcSEcCtD
Lidocaine—Somnolence—Lisinopril—dilated cardiomyopathy	0.000159	0.00538	CcSEcCtD
Lidocaine—Dizziness—Furosemide—dilated cardiomyopathy	0.000158	0.00533	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000154	0.00522	CcSEcCtD
Lidocaine—Pain—Lisinopril—dilated cardiomyopathy	0.000153	0.00517	CcSEcCtD
Lidocaine—Vomiting—Furosemide—dilated cardiomyopathy	0.000152	0.00513	CcSEcCtD
Lidocaine—Rash—Furosemide—dilated cardiomyopathy	0.00015	0.00508	CcSEcCtD
Lidocaine—Dermatitis—Furosemide—dilated cardiomyopathy	0.00015	0.00508	CcSEcCtD
Lidocaine—Headache—Furosemide—dilated cardiomyopathy	0.000149	0.00505	CcSEcCtD
Lidocaine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000147	0.00499	CcSEcCtD
Lidocaine—Urticaria—Lisinopril—dilated cardiomyopathy	0.000142	0.00481	CcSEcCtD
Lidocaine—Nausea—Furosemide—dilated cardiomyopathy	0.000142	0.00479	CcSEcCtD
Lidocaine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000132	0.00446	CcSEcCtD
Lidocaine—Asthenia—Lisinopril—dilated cardiomyopathy	0.000128	0.00434	CcSEcCtD
Lidocaine—Dizziness—Lisinopril—dilated cardiomyopathy	0.000118	0.004	CcSEcCtD
Lidocaine—Vomiting—Lisinopril—dilated cardiomyopathy	0.000114	0.00385	CcSEcCtD
Lidocaine—Rash—Lisinopril—dilated cardiomyopathy	0.000113	0.00382	CcSEcCtD
Lidocaine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000113	0.00381	CcSEcCtD
Lidocaine—Headache—Lisinopril—dilated cardiomyopathy	0.000112	0.00379	CcSEcCtD
Lidocaine—Nausea—Lisinopril—dilated cardiomyopathy	0.000106	0.00359	CcSEcCtD
Lidocaine—EGFR—Direct p53 effectors—GPX1—dilated cardiomyopathy	6.79e-05	0.0014	CbGpPWpGaD
Lidocaine—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	6.75e-05	0.00139	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—ITGB1—dilated cardiomyopathy	6.63e-05	0.00137	CbGpPWpGaD
Lidocaine—EGFR—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	6.57e-05	0.00136	CbGpPWpGaD
Lidocaine—EGFR—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	6.57e-05	0.00136	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	6.49e-05	0.00134	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—ITGB1—dilated cardiomyopathy	6.37e-05	0.00131	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—ITGB1—dilated cardiomyopathy	6.37e-05	0.00131	CbGpPWpGaD
Lidocaine—EGFR—Direct p53 effectors—FAS—dilated cardiomyopathy	6.35e-05	0.00131	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways in Glioblastoma—RAF1—dilated cardiomyopathy	6.34e-05	0.00131	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—PSEN2—dilated cardiomyopathy	6.33e-05	0.00131	CbGpPWpGaD
Lidocaine—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	6.23e-05	0.00129	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—RAC1—dilated cardiomyopathy	6.19e-05	0.00128	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—ITGB1—dilated cardiomyopathy	6.14e-05	0.00127	CbGpPWpGaD
Lidocaine—EGFR—EGF/EGFR Signaling Pathway—RPS6KB1—dilated cardiomyopathy	6.13e-05	0.00127	CbGpPWpGaD
Lidocaine—EGFR—Focal Adhesion—ITGB1—dilated cardiomyopathy	6.07e-05	0.00125	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—ITGB1—dilated cardiomyopathy	6.05e-05	0.00125	CbGpPWpGaD
Lidocaine—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	6e-05	0.00124	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—ANKRD1—dilated cardiomyopathy	5.93e-05	0.00123	CbGpPWpGaD
Lidocaine—EGFR—Regulation of Actin Cytoskeleton—RAC1—dilated cardiomyopathy	5.93e-05	0.00122	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—CD36—dilated cardiomyopathy	5.91e-05	0.00122	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	5.86e-05	0.00121	CbGpPWpGaD
Lidocaine—SCN5A—L1CAM interactions—EGFR—dilated cardiomyopathy	5.85e-05	0.00121	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—FASLG—dilated cardiomyopathy	5.69e-05	0.00118	CbGpPWpGaD
Lidocaine—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	5.65e-05	0.00117	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—CD36—dilated cardiomyopathy	5.65e-05	0.00117	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—TAZ—dilated cardiomyopathy	5.58e-05	0.00115	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—RAC1—dilated cardiomyopathy	5.57e-05	0.00115	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	5.54e-05	0.00114	CbGpPWpGaD
Lidocaine—EGFR—EGF/EGFR Signaling Pathway—RAC1—dilated cardiomyopathy	5.54e-05	0.00114	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—FAS—dilated cardiomyopathy	5.49e-05	0.00113	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—RAC1—dilated cardiomyopathy	5.49e-05	0.00113	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—CD36—dilated cardiomyopathy	5.43e-05	0.00112	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—CD36—dilated cardiomyopathy	5.43e-05	0.00112	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—RAC1—dilated cardiomyopathy	5.38e-05	0.00111	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—RAC1—dilated cardiomyopathy	5.33e-05	0.0011	CbGpPWpGaD
Lidocaine—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	5.26e-05	0.00109	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—CD36—dilated cardiomyopathy	5.24e-05	0.00108	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	5.21e-05	0.00108	CbGpPWpGaD
Lidocaine—EGFR—ErbB1 downstream signaling—RAF1—dilated cardiomyopathy	5.2e-05	0.00107	CbGpPWpGaD
Lidocaine—SCN9A—Axon guidance—RAF1—dilated cardiomyopathy	5.18e-05	0.00107	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—RAC1—dilated cardiomyopathy	5.16e-05	0.00107	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	5.16e-05	0.00107	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	5.14e-05	0.00106	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—RAC1—dilated cardiomyopathy	5.12e-05	0.00106	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—RAC1—dilated cardiomyopathy	5.12e-05	0.00106	CbGpPWpGaD
Lidocaine—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	5.07e-05	0.00105	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—SDHA—dilated cardiomyopathy	5.04e-05	0.00104	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	4.96e-05	0.00102	CbGpPWpGaD
Lidocaine—SCN3A—Axon guidance—RAF1—dilated cardiomyopathy	4.95e-05	0.00102	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—RAC1—dilated cardiomyopathy	4.94e-05	0.00102	CbGpPWpGaD
Lidocaine—EGFR—Focal Adhesion—RAC1—dilated cardiomyopathy	4.88e-05	0.00101	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—RAC1—dilated cardiomyopathy	4.86e-05	0.001	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	4.86e-05	0.001	CbGpPWpGaD
Lidocaine—SCN4A—Axon guidance—RAF1—dilated cardiomyopathy	4.76e-05	0.000982	CbGpPWpGaD
Lidocaine—SCN2A—Axon guidance—RAF1—dilated cardiomyopathy	4.76e-05	0.000982	CbGpPWpGaD
Lidocaine—SCN10A—Axon guidance—RAF1—dilated cardiomyopathy	4.59e-05	0.000947	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—PSEN2—dilated cardiomyopathy	4.52e-05	0.000933	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	4.51e-05	0.000932	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—ITGB1—dilated cardiomyopathy	4.32e-05	0.000891	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	4.24e-05	0.000876	CbGpPWpGaD
Lidocaine—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	4.22e-05	0.000872	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—RAF1—dilated cardiomyopathy	4.11e-05	0.000848	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	4.05e-05	0.000837	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—ITGB1—dilated cardiomyopathy	3.96e-05	0.000818	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—ANKRD1—dilated cardiomyopathy	3.94e-05	0.000814	CbGpPWpGaD
Lidocaine—EGFR—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	3.93e-05	0.000811	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—RAF1—dilated cardiomyopathy	3.93e-05	0.000811	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—RAF1—dilated cardiomyopathy	3.87e-05	0.000799	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	3.86e-05	0.000796	CbGpPWpGaD
Lidocaine—SCN5A—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	3.78e-05	0.00078	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—TAZ—dilated cardiomyopathy	3.71e-05	0.000766	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—RAF1—dilated cardiomyopathy	3.69e-05	0.000763	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—RAF1—dilated cardiomyopathy	3.69e-05	0.000763	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—CD36—dilated cardiomyopathy	3.68e-05	0.00076	CbGpPWpGaD
Lidocaine—EGFR—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	3.68e-05	0.000759	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—RAF1—dilated cardiomyopathy	3.68e-05	0.000759	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—RAF1—dilated cardiomyopathy	3.66e-05	0.000755	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—RAF1—dilated cardiomyopathy	3.64e-05	0.000752	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	3.63e-05	0.000749	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—ANKRD1—dilated cardiomyopathy	3.61e-05	0.000747	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—RAF1—dilated cardiomyopathy	3.57e-05	0.000737	CbGpPWpGaD
Lidocaine—SCN9A—Axon guidance—EGFR—dilated cardiomyopathy	3.55e-05	0.000733	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—RAF1—dilated cardiomyopathy	3.53e-05	0.000729	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—RAC1—dilated cardiomyopathy	3.52e-05	0.000726	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—RAC1—dilated cardiomyopathy	3.47e-05	0.000716	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—RAF1—dilated cardiomyopathy	3.42e-05	0.000707	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	3.42e-05	0.000707	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	3.42e-05	0.000707	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—TAZ—dilated cardiomyopathy	3.4e-05	0.000702	CbGpPWpGaD
Lidocaine—SCN3A—Axon guidance—EGFR—dilated cardiomyopathy	3.39e-05	0.000701	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—RAF1—dilated cardiomyopathy	3.39e-05	0.000701	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—RAF1—dilated cardiomyopathy	3.39e-05	0.000701	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—RAF1—dilated cardiomyopathy	3.39e-05	0.000701	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	3.36e-05	0.000694	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—SDHA—dilated cardiomyopathy	3.35e-05	0.000693	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—RAF1—dilated cardiomyopathy	3.35e-05	0.000691	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	3.27e-05	0.000676	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—RAF1—dilated cardiomyopathy	3.27e-05	0.000676	CbGpPWpGaD
Lidocaine—SCN4A—Axon guidance—EGFR—dilated cardiomyopathy	3.26e-05	0.000673	CbGpPWpGaD
Lidocaine—SCN2A—Axon guidance—EGFR—dilated cardiomyopathy	3.26e-05	0.000673	CbGpPWpGaD
Lidocaine—EGFR—Focal Adhesion—RAF1—dilated cardiomyopathy	3.24e-05	0.000668	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—RAF1—dilated cardiomyopathy	3.22e-05	0.000666	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	3.22e-05	0.000665	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	3.18e-05	0.000657	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	3.18e-05	0.000657	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—RAC1—dilated cardiomyopathy	3.18e-05	0.000657	CbGpPWpGaD
Lidocaine—SCN10A—Axon guidance—EGFR—dilated cardiomyopathy	3.14e-05	0.000649	CbGpPWpGaD
Lidocaine—EGFR—Spinal Cord Injury—TNF—dilated cardiomyopathy	3.09e-05	0.000639	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—SDHA—dilated cardiomyopathy	3.07e-05	0.000635	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	3.03e-05	0.000626	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	2.96e-05	0.000611	CbGpPWpGaD
Lidocaine—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	2.93e-05	0.000605	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ANKRD1—dilated cardiomyopathy	2.92e-05	0.000602	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ANKRD1—dilated cardiomyopathy	2.85e-05	0.000589	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—ITGB1—dilated cardiomyopathy	2.83e-05	0.000584	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	2.78e-05	0.000574	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	2.78e-05	0.000574	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—TAZ—dilated cardiomyopathy	2.74e-05	0.000566	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—TAZ—dilated cardiomyopathy	2.68e-05	0.000554	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	2.65e-05	0.000547	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	2.65e-05	0.000547	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	2.59e-05	0.000536	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—EGFR—dilated cardiomyopathy	2.53e-05	0.000523	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	2.5e-05	0.000517	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—SDHA—dilated cardiomyopathy	2.48e-05	0.000512	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ANKRD1—dilated cardiomyopathy	2.47e-05	0.00051	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	2.45e-05	0.000506	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	2.42e-05	0.000501	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—EGFR—dilated cardiomyopathy	2.42e-05	0.0005	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—TNF—dilated cardiomyopathy	2.41e-05	0.000498	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—CD36—dilated cardiomyopathy	2.41e-05	0.000498	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—ITGB1—dilated cardiomyopathy	2.4e-05	0.000495	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—RAF1—dilated cardiomyopathy	2.33e-05	0.000482	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	2.33e-05	0.000481	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—EGFR—dilated cardiomyopathy	2.33e-05	0.000481	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—EGFR—dilated cardiomyopathy	2.33e-05	0.000481	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—TAZ—dilated cardiomyopathy	2.32e-05	0.000479	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—TNF—dilated cardiomyopathy	2.31e-05	0.000476	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—RAF1—dilated cardiomyopathy	2.3e-05	0.000475	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—RAC1—dilated cardiomyopathy	2.27e-05	0.000469	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—AGTR2—dilated cardiomyopathy	2.26e-05	0.000466	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CXCL2—dilated cardiomyopathy	2.26e-05	0.000466	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—EGFR—dilated cardiomyopathy	2.24e-05	0.000463	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—TNF—dilated cardiomyopathy	2.22e-05	0.000458	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—TNF—dilated cardiomyopathy	2.22e-05	0.000458	CbGpPWpGaD
Lidocaine—EGFR—Disease—NPPA—dilated cardiomyopathy	2.22e-05	0.000457	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—EGFR—dilated cardiomyopathy	2.21e-05	0.000457	CbGpPWpGaD
Lidocaine—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	2.15e-05	0.000444	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	2.15e-05	0.000444	CbGpPWpGaD
Lidocaine—EGFR—Disease—PSEN2—dilated cardiomyopathy	2.15e-05	0.000443	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—TNF—dilated cardiomyopathy	2.14e-05	0.000441	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—CD36—dilated cardiomyopathy	2.13e-05	0.00044	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—RAF1—dilated cardiomyopathy	2.11e-05	0.000436	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	2.1e-05	0.000434	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—SDHA—dilated cardiomyopathy	2.1e-05	0.000434	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CXCR3—dilated cardiomyopathy	2.1e-05	0.000434	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—CD36—dilated cardiomyopathy	2.04e-05	0.000422	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—ADRB1—dilated cardiomyopathy	2.03e-05	0.00042	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	2.03e-05	0.000419	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	2.02e-05	0.000418	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	2.01e-05	0.000415	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—RAC1—dilated cardiomyopathy	2.01e-05	0.000414	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—RAC1—dilated cardiomyopathy	1.93e-05	0.000398	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	1.91e-05	0.000394	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	1.89e-05	0.00039	CbGpPWpGaD
Lidocaine—SLC22A5—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.88e-05	0.000388	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	1.83e-05	0.000378	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—AGTR1—dilated cardiomyopathy	1.74e-05	0.000359	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	1.72e-05	0.000356	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	1.72e-05	0.000355	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	1.71e-05	0.000353	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—ADRB2—dilated cardiomyopathy	1.65e-05	0.00034	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	1.63e-05	0.000336	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	1.61e-05	0.000333	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—EGFR—dilated cardiomyopathy	1.58e-05	0.000326	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—RAF1—dilated cardiomyopathy	1.51e-05	0.000311	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—TNF—dilated cardiomyopathy	1.5e-05	0.00031	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.5e-05	0.00031	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	1.46e-05	0.000302	CbGpPWpGaD
Lidocaine—EGFR—Immune System—ITGB1—dilated cardiomyopathy	1.45e-05	0.0003	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—GPX1—dilated cardiomyopathy	1.37e-05	0.000283	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—CD36—dilated cardiomyopathy	1.33e-05	0.000276	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.33e-05	0.000275	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.33e-05	0.000275	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—RAF1—dilated cardiomyopathy	1.33e-05	0.000275	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	1.33e-05	0.000274	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.28e-05	0.000264	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—RAC1—dilated cardiomyopathy	1.28e-05	0.000264	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—RAF1—dilated cardiomyopathy	1.28e-05	0.000264	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.25e-05	0.000258	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	1.25e-05	0.000257	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.24e-05	0.000256	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CD36—dilated cardiomyopathy	1.24e-05	0.000256	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—AGT—dilated cardiomyopathy	1.22e-05	0.000252	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—AGT—dilated cardiomyopathy	1.2e-05	0.000248	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.2e-05	0.000248	CbGpPWpGaD
Lidocaine—EGFR—Immune System—RAC1—dilated cardiomyopathy	1.17e-05	0.000241	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	1.13e-05	0.000233	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.12e-05	0.000232	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	1.12e-05	0.00023	CbGpPWpGaD
Lidocaine—EGFR—Disease—RAC1—dilated cardiomyopathy	1.08e-05	0.000223	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	1.06e-05	0.000219	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.04e-05	0.000215	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.03e-05	0.000212	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.02e-05	0.00021	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—TNF—dilated cardiomyopathy	9.84e-06	0.000203	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.73e-06	0.000201	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	9.14e-06	0.000189	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	9.11e-06	0.000188	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	8.91e-06	0.000184	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	8.87e-06	0.000183	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	8.67e-06	0.000179	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—RAF1—dilated cardiomyopathy	8.48e-06	0.000175	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.36e-06	0.000173	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—GPX1—dilated cardiomyopathy	8.35e-06	0.000172	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CD36—dilated cardiomyopathy	8.13e-06	0.000168	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	7.99e-06	0.000165	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	7.81e-06	0.000161	CbGpPWpGaD
Lidocaine—EGFR—Immune System—RAF1—dilated cardiomyopathy	7.75e-06	0.00016	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—RAC1—dilated cardiomyopathy	7.55e-06	0.000156	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—AGT—dilated cardiomyopathy	7.32e-06	0.000151	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—AGT—dilated cardiomyopathy	7.22e-06	0.000149	CbGpPWpGaD
Lidocaine—EGFR—Disease—RAF1—dilated cardiomyopathy	7.15e-06	0.000148	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GPX1—dilated cardiomyopathy	6.74e-06	0.000139	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	6.59e-06	0.000136	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CD36—dilated cardiomyopathy	6.56e-06	0.000135	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	6.46e-06	0.000133	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	6.41e-06	0.000132	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—AGT—dilated cardiomyopathy	5.91e-06	0.000122	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	5.77e-06	0.000119	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	5.7e-06	0.000118	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	5.55e-06	0.000115	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—RAF1—dilated cardiomyopathy	5.01e-06	0.000103	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	5e-06	0.000103	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	4.97e-06	0.000103	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CD36—dilated cardiomyopathy	4.84e-06	9.99e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	4.68e-06	9.67e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	4.64e-06	9.59e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	4.56e-06	9.42e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	4.52e-06	9.34e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—AGT—dilated cardiomyopathy	4.36e-06	9e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	4.11e-06	8.48e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	4.07e-06	8.41e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	3.97e-06	8.19e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	3.86e-06	7.98e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	3.48e-06	7.18e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	3.06e-06	6.32e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.98e-06	6.16e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.68e-06	5.54e-05	CbGpPWpGaD
